- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01520493
Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Pulmonary artery hypertension (PAH) is a rare, severe disease, characterized by a progressive increase in pulmonary vascular resistance ultimately leading to right ventricular (RV) failure and premature death. PAH may be idiopathic (IPAH) or may be also related to various conditions like portal hypertension, HIV infection, left to right shunt, connective tissue diseases such as scleroderma (PAHSSc). PAH is defined as a mean pulmonary artery pressure (mPAP) of > 25 mmHg at rest. Symptoms include dyspnea and fatigue resulting in restricted exercise capacity and poor quality of life. The agents currently approved for treatment of PAH are prostanoids (i.v. epoprostenol or s.c./i.v. treprostinil), endothelin-receptor antagonists (ambrisentan, bosentan and sitaxsentan), and phosphodiesterase type 5-inhibitors (sildenafil and tadalafil). These therapies have been shown to improve pulmonary hemodynamics, exercise capacity, quality of life and survival. Indeed, recent studies described a three year survival higher than 80%. This improved survival is associated with major challenges for clinicians as most patients remain with limited exercise capacity and poor quality of life. A clear understanding of exercise physiopathology is thus mandatory to specifically address mechanisms responsible for this exercise limitation and eventually improve patients' management.
In order to better characterize the exercise physiopathology in PAH, the general objective of this research is to systematically examine blood flow distribution and limb muscles microcirculation at rest and during submaximal exercise in PAH. The limited link between traditional measures of pulmonary hemodynamic impairment and functional capacity confirms that exercise physiopathology in PAH is not well understood. Although peripheral muscle dysfunction and exercise intolerance are certainly multifactorial in origin and are unlikely to be explained by a single mechanism, an altered skeletal muscle microcirculation could represent a unifying mechanism to explain similarities in skeletal muscle dysfunction and exercise intolerance in PAH. The investigators plan to use a multimodality approach to provide comprehensive information regarding skeletal muscle perfusion in PAH. For example, the investigators will be able to know if there is some relationship between muscle perfusion heterogeneity (arterial spin labeling MRI) and microvascular oxygenation or muscle oxygen consumption (NIRS). Muscle oxygen delivery could also be influenced by cardiac function or hypoxemia. These methods should thus be viewed as complimentary and will help to separate differences in cardiac function, quadriceps global perfusion, perfusion heterogeneity and oxygenation and their consequences on skeletal muscle function and exercise tolerance in PAH versus controls.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Québec, Canadá, G1V 4G5
- Institut Universitaire de Cardiologie et de Pneumologie de Quebec
-
Québec, Canadá, G1V 4G5
- Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ)
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- WHO functional class II-III idiopathic PAH patients;
- WHO functional class II-III PAH-SSc patients with hemodynamic assessment <6 months;
- sedentary healthy subjects;
- subjects with limited SSc (without PAH) individually matched for age, gender, height and weight.
Exclusion Criteria:
- unstable clinical condition (e.g. recent syncope, WHO functional class IV);
- a six-minute walked distance < 300 meters during routine follow-up at the pulmonary hypertension clinic;
- left ventricular ejection fraction < 40%;
- restrictive (lung fibrosis on CT scan or total lung capacity < 80% of predicted) or obstructive lung disease (FEV1/FVC < 70%);
- contraindication for MRI;
- body mass index > 30 kg/m2;
- known locomotor abnormality.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Exercise
All patients are subject to this Arm.
|
Consists of a 3-min unloaded exercise, followed by a progressive RAMP protocol (10 watts/min) up to 70% of peak workload followed by 3 min.
of cycling at constant workload (70% peak workload) (total exercise duration of 25 min.).
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Muscle microcirculation during submaximal exercise
Periodo de tiempo: day 3
|
Thigh muscles overall perfusion and perfusion heterogeneity will be assessed by pulsed arterial spin labeling magnetic resonance imaging (ASL MRI).
MRI allows the acquisition of both spatially and temporally localized perfusion measurements within working muscle.
|
day 3
|
Cardiac output during submaximal exercise
Periodo de tiempo: day 3
|
Cardiac MRI.
Right after muscles perfusion heterogeneity assessment by MRI (both at rest and following the same exercise protocol), cardiac MRI will be performed with the same 1.5 Tesla MRI.
|
day 3
|
Muscle sympathetic nerve activity (MSNA)
Periodo de tiempo: day 2
|
MSNA will be assessed by microneurography and measures sympathetic nerve traffic directed to muscle circulation.
All measurements will be performed under quiet resting supine conditions before non-MRI exercise.
|
day 2
|
Quadriceps muscle function
Periodo de tiempo: day 2
|
Quadriceps muscle function will be assessed using voluntary and non-volitional measurements: Strength of the dominant quadriceps will be evaluated using the Biodex System 4 Pro (Biodex Medical Systems, 20 Ramsay Road, Shirley, New York). Non-volitional dominant quadriceps endurance will be evaluated by magnetic stimulation of the femoral nerve using the Magstim Rapid 2 system (Magstim Co. Ltd., Whitland, Dyfed, Wales, UK) coupled with the Biodex System 4 Pro, allowing measurements of intrinsic muscle endurance properties independent of central drive. |
day 2
|
Relationship between in vivo muscle microcirculation and capillarity
Periodo de tiempo: day 1
|
Capillarity and angiogenesis-related gene expression in muscle biopsy.
In order to explore the relationship between in vivo muscle microcirculation and capillarity, percutaneous biopsy specimens of the vastus lateralis muscle of the nondominant leg will be taken at midthigh as described by Bergström.
|
day 1
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Steeve Provencher, MD, MSc, Fondation IUCPQ
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- Microcirculation_Local funds
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Hipertensión arterial pulmonar
-
Dartmouth-Hitchcock Medical CenterDartmouth CollegeTerminadoPresión arterial | Anestesia | Línea ArterialEstados Unidos
-
Auburn UniversityActivo, no reclutandoDormir | Presión arterial | Disfunción endotélica | Racismo | Rigidez ArterialEstados Unidos
-
AHEPA University HospitalTerminadoRigidez arterial | Monitoreo ambulatorio de la presión arterialGrecia
-
Unity Health TorontoTerminadoRigidez arterial, presión arterialCanadá
-
BLZ Technology (Wuhan) Co.,LtdAún no reclutandoPresión arterial | Anestesia general | Línea Arterial | La frecuencia del pulso
-
CID S.p.A.Meditrial Europe Ltd.Aún no reclutandoEnfermedad arterial periférica oclusiva | Enfermedad Arterial PeriféricaItalia
-
Marissa JarosinskiReclutamientoEnfermedad arterial periférica oclusiva | Enfermedad vascular periférica | Enfermedad Arterial Periférica | Clopidogrel, metabolismo deficiente de | Enfermedad ArterialEstados Unidos
-
Istituto Auxologico ItalianoReclutamientoHipertensión arterial | Monitoreo ambulatorio de la presión arterial | Determinación de la presión arterial | Monitoreo de la presión arterial en el hogarItalia
-
ROX Medical, Inc.TerminadoHipertensión | Presión Arterial, Alta | Presión Arterial, Resistente | Presión Arterial, No ControladaReino Unido, Países Bajos, Bélgica
-
University of JyvaskylaBusiness Finland; Finnish Foundation for Cardiovascular Research; Harvia Finland...TerminadoPresión arterial | Factor de riesgo cardiovascular | Rigidez arterialFinlandia